195 related articles for article (PubMed ID: 29397532)
1. Changes in Heart Rate Associated with Exenatide Once Weekly: Pooled Analysis of Clinical Data in Patients with Type 2 Diabetes.
Marso SP; Hardy E; Han J; Wang H; Chilton RJ
Diabetes Ther; 2018 Apr; 9(2):551-564. PubMed ID: 29397532
[TBL] [Abstract][Full Text] [Related]
2. Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) Therapy Adherence for Patients with Type 2 Diabetes in a Medicare Population.
Nguyen H; Dufour R; Caldwell-Tarr A
Adv Ther; 2017 Mar; 34(3):658-673. PubMed ID: 28078541
[TBL] [Abstract][Full Text] [Related]
3. Retrospective study of adherence to glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes mellitus in the United States.
Johnston SS; Nguyen H; Felber E; Cappell K; Nelson JK; Chu BC; Kalsekar I
Adv Ther; 2014 Nov; 31(11):1119-33. PubMed ID: 25408484
[TBL] [Abstract][Full Text] [Related]
4. Treatment Patterns and Persistence With GLP-1 RA Treatments Among Patients With Type 2 Diabetes in France: A Retrospective Cohort Analysis.
Zimner Rapuch S; Divino V; Norrbacka K; Boye K; Lebrec J; Rosilio M; DeKoven M; Guerci B
Diabetes Ther; 2021 May; 12(5):1553-1567. PubMed ID: 33864629
[TBL] [Abstract][Full Text] [Related]
5. Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: an integrated analysis of 4,328 patients.
MacConell L; Gurney K; Malloy J; Zhou M; Kolterman O
Diabetes Metab Syndr Obes; 2015; 8():241-53. PubMed ID: 26056482
[TBL] [Abstract][Full Text] [Related]
6. Liraglutide Versus Exenatide Once Weekly: Persistence, Adherence, and Early Discontinuation.
Yu M; Xie J; Fernandez Lando L; Kabul S; Swindle RW
Clin Ther; 2016 Jan; 38(1):149-60. PubMed ID: 26706658
[TBL] [Abstract][Full Text] [Related]
7. Exenatide Once Weekly for Management of Type 2 Diabetes: A Review.
Inaishi J; Saisho Y
Clin Pharmacol; 2022; 14():19-26. PubMed ID: 35422660
[TBL] [Abstract][Full Text] [Related]
8. Pancreatitis Incidence in the Exenatide BID, Exenatide QW, and Exenatide QW Suspension Development Programs: Pooled Analysis of 35 Clinical Trials.
Vetter ML; Johnsson K; Hardy E; Wang H; Iqbal N
Diabetes Ther; 2019 Aug; 10(4):1249-1270. PubMed ID: 31077072
[TBL] [Abstract][Full Text] [Related]
9. Glucagon-Like Peptide 1 Receptor Agonists in Type 2 Diabetes Mellitus: Data from a Real-World Study in Spain.
Norrbacka K; Sicras-Mainar A; Lebrec J; Artime E; Díaz S; Tofé-Povedano S; Hernández I; Romera I
Diabetes Ther; 2021 May; 12(5):1535-1551. PubMed ID: 33860927
[TBL] [Abstract][Full Text] [Related]
10. Long-term management of type 2 diabetes with glucagon-like peptide-1 receptor agonists.
Courtney H; Nayar R; Rajeswaran C; Jandhyala R
Diabetes Metab Syndr Obes; 2017; 10():79-87. PubMed ID: 28331351
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review.
Aroda VR; Henry RR; Han J; Huang W; DeYoung MB; Darsow T; Hoogwerf BJ
Clin Ther; 2012 Jun; 34(6):1247-1258.e22. PubMed ID: 22608780
[TBL] [Abstract][Full Text] [Related]
12. Exenatide: pharmacokinetics, clinical use, and future directions.
Knop FK; Brønden A; Vilsbøll T
Expert Opin Pharmacother; 2017 Apr; 18(6):555-571. PubMed ID: 28085521
[TBL] [Abstract][Full Text] [Related]
13. Retrospective study comparing healthcare costs and utilization between commercially insured patients with type 2 diabetes mellitus who are newly initiating exenatide once weekly or liraglutide in the United States.
Johnston SS; Nguyen H; Cappell K; Nelson JK; Chu BC; Kalsekar I
J Med Econ; 2015; 18(9):666-77. PubMed ID: 25867133
[TBL] [Abstract][Full Text] [Related]
14. A Network Meta-analysis Comparing Exenatide Once Weekly with Other GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus.
Kayaniyil S; Lozano-Ortega G; Bennett HA; Johnsson K; Shaunik A; Grandy S; Kartman B
Diabetes Ther; 2016 Mar; 7(1):27-43. PubMed ID: 26886440
[TBL] [Abstract][Full Text] [Related]
15. Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis.
Sun F; Wu S; Guo S; Yu K; Yang Z; Li L; Zhang Y; Quan X; Ji L; Zhan S
Diabetes Res Clin Pract; 2015 Oct; 110(1):26-37. PubMed ID: 26358202
[TBL] [Abstract][Full Text] [Related]
16. Real-world glycemic outcomes in patients with type 2 diabetes initiating exenatide once weekly and liraglutide once daily: a retrospective cohort study.
Saunders WB; Nguyen H; Kalsekar I
Diabetes Metab Syndr Obes; 2016; 9():217-23. PubMed ID: 27486339
[TBL] [Abstract][Full Text] [Related]
17. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
Deacon CF; Mannucci E; Ahrén B
Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
[TBL] [Abstract][Full Text] [Related]
18. Tumour Risk with Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus Patients: A Systematic Review.
Guo X; Yang Q; Dong J; Liao L; Zhang W; Liu F
Clin Drug Investig; 2016 Jun; 36(6):433-41. PubMed ID: 26979594
[TBL] [Abstract][Full Text] [Related]
19. Semaglutide Once-Weekly Persistence and Adherence Versus Other GLP-1 RAs in Patients with Type 2 Diabetes in a US Real-World Setting.
Uzoigwe C; Liang Y; Whitmire S; Paprocki Y
Diabetes Ther; 2021 May; 12(5):1475-1489. PubMed ID: 33837922
[TBL] [Abstract][Full Text] [Related]
20. Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment.
Fineman MS; Mace KF; Diamant M; Darsow T; Cirincione BB; Booker Porter TK; Kinninger LA; Trautmann ME
Diabetes Obes Metab; 2012 Jun; 14(6):546-54. PubMed ID: 22236356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]